About us   Contacts   Links   Information in Russian 
Research programms
Publications

Abstracts 2017


1. Laktionov K.K., Bolotina L.V., Breder V.V., Danilova A.S., Moiseenko F.V., Nikitina T.P., Orlova R.V., Filippova E.A., Protsenko S.A., Ionova T.I. Clinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+ line treatment: interim analysis of expanded access program. Annals of Oncology. 2017; 28 (Suppl.2): P. 41. doi:10.1093/annonc/mdx091. https://academic.oup.com/annonc/article/28/suppl_2/mdx091.033/3799695?searchresult=1

2. Tseitlin G., Karelin G., Borodina I., Kokoreva M., Ionova T., Nikitina T. Health-related quality of life in children with brain tumors and acute lymphoblastic leukemia after treatment: a comparative study. Abstracts of the 2017 World Congress of Psycho-oncology, 14-18 August 2017, Berlin, Germany. Psycho-Oncology. 2017; 26 (Suppl. 3): P. 28. http://www.ipos2017.com/files/content/downloads/IPOS2017_Abstractbook_.pdf

3. Ionova T., Bulieva N., Vinogradova O., Zinkovskaya A., Lipatova D., Lomaia E., Nikitina T., Novitskaya N., Trifonova E., Usacheva E., Chukavina M., Shumkova M. Quality of Life (QoL), Efficacy and Safety of Treatment with Dasatinib as Front-line Therapy or after Early Switching from Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP CML): a Real World Data. Clinicheskaya onkogematologia. 2017; 10 (4): 546–547. http://bloodjournal.ru/wp-content/uploads/2017/10/12_1.pdf

4. Ionova T., Bulieva N., Vinogradova O., Gritsenko T., Zinkovskaya A., Kozlova L., Kuchma G., Lipatova D., Lomaia E., Machulaytene E., Nikitina T., Novitskaya N., Trifonova E., Usacheva E., Shneider T. Impact of symptom burden on quality of life (QoL) in patients with chronic myeloid leukemia in chronic phase (CML CP). Clinicheskaya onkogematologia. 2017; 10 (4): 548–549.http://bloodjournal.ru/wp-content/uploads/2017/10/12_1.pdf

5. Moiseenko F.V., Laktionov K.K., Arzumanyan A.L. et al. Observational study of the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: interim analysis. J Clin Oncol. 2017; 35 (Suppl; abstr e14593). https://meetinglibrary.asco.org/record/145234/abstract

6. Laktionov K.K., Arzumanyan A.L., Bolotina L.V., Breder V.V., Buevich N.N., Danilova A.S., Filippova E.A., Kornietskaya A.L., Kramchaninov M.M., Kushniruk E.K., Latipova D.H., Lipatova D.A., Moiseenko F.V., Nikitina T.P., Orlov S.V., Orlova R.V., Protsenko S.A., Sarantseva K.A., Stroyakovskiy D.L., Ionova T.I. Efficacy of nivolumab as second and further line of treatment and quality of life in patients with advanced refractory non-small cell lung cancer: interim results of prospective observational study. Proceedings of III St. Petersburg International Oncology Forum "White Nights 2017», 91–92 (in Russian)

7. Laktionov K.K., Arzumanyan A.L., Bolotina L.V., Breder V.V., Buevich N.N., Danilova A.S., Filippova E.A., Kornietskaya A.L., Kramchaninov M.M., Kushniruk E.K., Latipova D.H., Moiseenko F.V., Nikitina T.P., Orlov S.V., Orlova R.V., Protsenko S.A., Sarantseva K.A., Stroyakovskiy D.L., Ionova T.I. Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: interim analysis. Annals of Oncology. 2017; 28 (Suppl. 5): P. 470. https://academic.oup.com/annonc/article/28/suppl_5/mdx380.020/4109375?searchresult=1

8. Ionova T.I., Arzumanyan A.L., Bolotina L.V., Breder V.V., Buevich N.N., Danilova A.S., Filippova E.A., Kornietskaya A.L., Kramchaninov M.M., Kushniruk E.K., Latipova D.H., Lipatova D.A. , Malova O.A., Moiseenko F.V., Nikitina T.P., Orlov S.V., Orlova R.V., Protsenko S.A., Sarantseva K.A., Stroyakovskiy D.L., Zinkovskaya A.V., Laktionov K.K. Quality of life and clinical outcomes of nivolumab as 2+ line treatment in advanced refractory NSCLC pts: interim analysis. Journal of Thoracic Oncology. 2017; Vol. 12 (№11, Supplement 2): P. 1916. http://www.jto.org/article/S1556-0864(17)31445-4/fulltext

9. Tseitlin G., Karelin G., Borodina I., Kokoreva M., Nikitina T. Ionova T. Quality of life assessment in children and adolescents with cancer as a criterion of effectiveness of rehabilitation. Proceeding of the Ist National Congress with International Participation «Rehabilitation – ХХI Century: traditions and innovations». 2017; 270–271. (in Russian)

10. Ionova T.I., Arzumanyan A.L., Bolotina L.V., Breder V.V., Buevich N.N., Danilova A.S., Filippova E.A., Kornietskaya A.L., Kramchaninov M.M., Kushniruk E.K., Latipova D.H., Lipatova D.A., Malova O.A., Moiseenko F.V., Nikitina T.P., Orlov S.V., Orlova R.V., Protsenko S.A., Sarantseva K.A., Stroyakovskiy D.L., Zinkovskaya A.V., Laktionov K.K. Quality of life and clinical outcomes of nivolumab as 2+ line treatment in advanced refractory NSCLC pts: interim analysis. Abstract Book of IASLC 18th World Congress of Lung Cancer, 2017, P. 227. https://s3.amazonaws.com/iaslc/pdf/WCLC2017_Abstract_Book_Web.pdf

11. IonovaT., BulievaN., GolenkovA., GritsenkoT., KozlovaL., KuchmaG., LomaiaE., MachulayteneE., NikitinaT., NovitskayaN., UsachevaE., ShneiderT., TrifonovaE., VinogradovaO., ZinkovskayaA.. Is quality of life (QOL) predictive for clinical response in chronic phase-chronic myeloid leukemia (CP-CML) patients treated with dasatinib? Blood. 2017; 130 (Suppl 1); 2181. http://www.bloodjournal.org/content/130/Suppl_1/2181

12. P. Goswami, S. Salek, T. Ionova, E. Oliva, A. Fielding, M. Karakantza, S. Al-Ismail, G. Collins, S. McCpnnell, C. Langton, D. Jennings, R. Else, W. Kell. HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice. Blood. 2017; 130 (Suppl 1):2176. http://www.bloodjournal.org/content/130/Suppl_1/2176









© Создание сайтов

Последнее обновление (last update): 29-03-2024









Яндекс цитирования